Drug Profile
Research programme: protozoal infections therapeutics - Astellas/AIST
Alternative Names: Parasitic infections therapeutics - Astellas/AISTLatest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Astellas Pharma; National Institute of Advanced Industrial Science and Technology
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease
- Discontinued Protozoan infections
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Chagas-disease in Japan
- 01 Apr 2016 Astellas Pharma and National Institute of Advanced Industrial Science and Technology entered into a new collaborative research agreement for the development of therapies for Chagas' disease
- 01 Apr 2016 Discontinued for Protozoal infections in Japan (unspecified route)